In cases like this, where the drug being tested (Velcade) received FDA approval while the given trial was in progress, the data-monitoring board must be under intense pressure to end the control arm for fear that the control-arm patients would drop out (and get Velcade on their own) if not offered the opportunity to cross over.
News 
Market Data 
Discover 
